Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bioverativ

- PMLiVE

Sanofi wins two at PMEA 2013

Awards haul also includes four high commendations

The logistics of orphan drugs

Managing a rare disease global access programme, the goal is to minimise risk and get the drug to the patient on time

Sanofi reception

Sanofi moves closer to arthritis drug filing

Reports positive late-stage results for sarilumab

- PMLiVE

Rare disease strategy for the UK launched

Aims to improve understanding and boost research

Sanofi reception

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials

Shire Basingstoke

Shire snaps up Viropharma to build $2bn rare disease unit

Gains access to Cinryze in expensive but 'strategically sound' deal

Shire Basingstoke

Shire mulls UK job cuts

Enters “employee consultation process” for research site in Basingstoke

- PMLiVE

Orphan status for Stem Cell’s leukaemia drug

Tigecycline wins FDA rare disease designation

Sanofi reception

Sanofi returns to growth in Q3

Diabetes products and Genzyme help company overcome patent cliff

- PMLiVE

FDA sets up rare disease research fund

Will invest $14m across 15 orphan drug projects

- PMLiVE

Sanofi launches a monster mobile diabetes game

Monster Manor iPhone and Android apps aim to encourage better management of the condition

Orphan drugs: the early access regulatory environment

Despite considerable variation to the rules for unlicensed orphan drugs, there are some clear first steps for a global access programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links